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Abstract
Background: In the PREVAIL study, enzalutamide provided significant improve-
ments versus placebo in clinical outcomes in chemotherapy-naïve men with
metastatic castration-resistant prostate cancer (mCRPC). The association of
post-treatment prostate-specific antigen (PSA) decline with clinical outcomes
may provide important prognostic information.
Objective: To evaluate associations between the magnitude of PSA decline from
baseline to month 3 and clinical outcomes among enzalutamide recipients.
Design, setting, and participants: This was a post hoc retrospective analysis of
PREVAIL, an international, randomized, double-blind, placebo-controlled phase
3 study. Men with mCRPC and no prior chemotherapy from the enzalutamide arm
were included (n = 872). Patients were grouped by confirmed maximal PSA decline
from baseline to month 3 of treatment (n = 795 evaluable).
Outcome measurements and statistical analysis: Primary outcomes were overall
survival and radiographic progression-free survival. Secondary outcomes included
PSA progression-free survival, radiographic response, and degradation of Func-
tional Assessment of Cancer Therapy-Prostate score, which were estimated using
the Kaplan-Meier method.
Results and limitations: Following 3 mo of enzalutamide treatment, 88% (701/
795), 80% (639/795), and 39% (307/795) of patients had postbaseline confirmed
maximal PSA declines of 30%, 50%, and 90%, respectively, whereas 12% (94/
795) had no confirmed maximal PSA decline or a decline of <30%. Greater degrees
of PSA decline within the first 3 mo of enzalutamide treatment were increasinglyger
uted equally to this manuscript.
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higher objective soft-tissue responses, and longer time to quality-of-life deterioration
than no PSA decline or declines of <30% from baseline. PSA flares (rise followed by fall)
after enzalutamide treatment were rare (<1%).
Conclusions: The magnitude of PSA decline after 3 mo of enzalutamide therapy was
strongly associated with better clinical and patient-reported outcomes. This updated
prognostic information is of clinical value to this patient population and their health
care providers.
Patient summary: We report that decreases in PSA levels are closely linked to better health
and survival after 3 mo of enzalutamide treatment in men with metastatic prostate cancer.
The PREVAIL trial is registered at clinicaltrials.gov as NCT01212991.
© 2018 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Treatment for men with metastatic castration-resistant
prostate cancer (mCRPC) has substantially evolved with the
use of novel hormonal therapies, and at present enzaluta-
mide or abiraterone acetate with prednisone is recom-
mended before use of cytotoxic chemotherapy [1,2]. These
hormonal therapies improve survival and delay radiograph-
ic and symptomatic disease progression, but the degree and
durability of responses vary.
Serum levels of prostate-specific antigen (PSA), an andro-
gen receptor (AR)-regulated protein, correlate strongly with
disease burden and prognosis in the mCRPC setting, and levels
decline significantly with AR pathway inhibition [1,3–5]. Doc-
etaxel was the first systemic therapy for which it was
demonstrated that declines in PSA are associated with better
overall survival (OS) and quality of life (QoL) in mCRPC [3,6]. In
these studies, PSA declines following 3 mo of docetaxel were
strongly associated with survival and better outcomes, but did
not fulfill surrogacy criteria. Although current clinical research
guidelines (Prostate Cancer Clinical Trials Working Group
3 [PCWG3]) do not recommend PSA as a surrogate endpoint for
regulatory approval, PSA changes along with imaging and
patient-reported outcomes may provide critical prognostic
information during therapy that justify continuing therapy or
considering alternative approaches.
We evaluated PSA declines in the PREVAIL study, in
which enzalutamide provided significant improvements
versus placebo [1,2,7]. The aim of this post hoc analysis was
to characterize the prognostic association between the
magnitude of a PSA decline from baseline to month 3 and
clinical outcomes. We found that early PSA declines with
enzalutamide were highly associated with better long-term
clinical outcomes and patient-reported outcomes.
2. Patients and methods
2.1. Study design and conduct
We conducted a post hoc retrospective analysis of the prospective
PREVAIL study (NCT01212991; n = 1717), an international, randomized,
double-blind, placebo-controlled phase 3 trial. The PREVAIL study design
and eligibility criteria, as well as baseline characteristics and outcomes,
were published previously [1].Patients were randomized 1:1 to receive oral enzalutamide 160 mg or
placebo once daily until intolerance, confirmed radiographic disease
progression, or initiation of another therapy for prostate cancer. PREVAIL
was stopped after a planned interim survival analysis at 540 reported deaths
showed a benefit in favor of enzalutamide (data cutoff September 16, 2013)
[1]. Results of the PREVAIL co-primary endpoints of OS and radiographic
progression-free survival (rPFS), also used for the current PSA decline
analysis, were previously published [1,7]. These patients had CRPC and were
either asymptomatic or only mildly symptomatic. A total of 626 patients
(72%) in the enzalutamide group and 532 patients (63%) in the placebo group
were alive at the data cutoff date (29% reduction in risk of death; hazard ratio
[HR] 0.71, 95% confidence interval [CI] 0.60–0.84; p < 0.001) [1,8].
2.2. Analysis of PSA decline
Scheduled PSA measurements were conducted at screening, immedi-
ately before the first dose of the study drug, at weeks 13 (month 3), 17, 21,
and 25, and every 12 wk thereafter. For this post hoc analysis, men from
the enzalutamide arm of PREVAIL were grouped into four categories for
the confirmed maximal PSA decline from baseline to month 3 following
treatment initiation as follows: no decline or a decline <30%; 30%
decline; 50% decline; and 90% decline (Fig. 1).
Confirmation required a PSA decline on one or more consecutive
visits after month 3. The best overall PSA decline at any point while on
enzalutamide therapy was also summarized without stratification. A PSA
flare phenomenon was defined as a documented transient PSA increase
or no decline within 3 mo on enzalutamide treatment followed by a
decline of 30% compared with the pretreatment baseline PSA level at
later time points.
2.3. Assessment of radiographic progression
Radiographic disease in soft tissue was evaluated using computed
tomography or magnetic resonance imaging and in bone using
technetium bone scintigraphy at screening, weeks 9, 17, and 25, and
every 12 wk thereafter [1]. Radiographic progression was determined
using Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST)
for soft tissue or criteria adapted from the Prostate Cancer Clinical Trials
Working Group 2 for osseous disease [9–11].
Radiographic disease progression in bone (2 new lesions on
radionuclide bone scan) observed at week 9 required two additional new
lesions on a confirmatory scan 6 wk later; radiographic disease
progression in bone observed after week 9 required persistence of
two new lesions on a confirmatory scan 6 wk later. rPFS was defined as
the time from randomization to the first objective evidence of
radiographic disease progression (assessed by blinded independent
central review) or death due to any cause within 168 d after treatment
Fig. 1 – CONSORT diagram showing the relationship between the PREVAIL trial population and the subgroups analyzed by prostate-specific antigen
(PSA) decline in the enzalutamide arm.
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randomization to death due to any cause.
2.4. Functional Assessment of Cancer Therapy-Prostate
The Functional Assessment of Cancer Therapy-Prostate (FACT-P) QoL
questionnaire was used to assess patient function in four domains
(physical, social/family, emotional, and functional well-being) and global
QoL, with higher scores representing better QoL. A validated version of
the questionnaire was completed by the patient on day 1, at weeks 5 and
13, and every 12 wk thereafter, and the time from randomization to date
of degradation of FACT-P score was evaluated. Degradation in FACT-P
score was defined as a 10-point decrease from baseline in total score.
Degradation on individual FACT-P domains was defined as a 3-point
decrease from baseline score for that domain.
2.5. Analysis of outcomes
This post hoc analysis was designed to investigate the association
between PSA decline by 3 mo and OS, and with the secondary outcomes
of rPFS, PSA PFS, RECIST response, and time to FACT-P degradation. Time
to best overall PSA decline was the duration from first treatment date tothe date of the lowest postbaseline PSA measurement. Estimates of the
median and 95% CIs for the time-to-event analyses were determined
using the Kaplan-Meier method for OS, rPFS, PSA progression, and FACT-
P degradation. The HR was determined using an unstratified Cox
regression model (with PSA decline groups as the only covariate) and was
relative to the no-decline or decline <30% group. For the HR 95% CIs, an
upper limit value of <1.00 indicated benefit in favor of the PSA decline
groups. A two-sided Fisher’s exact test with a significance level of
0.05 was used to compare the PSA decline groups with the no-decline or
decline <30% group for best overall RECIST response. The data cutoff
dates were September 16, 2013 for OS, PSA progression, FACT-P
degradation, and best overall soft-tissue response, and May 6,
2012 for rPFS. SAS Enterprise Guide 7.1 (SAS Institute, Cary, NC, USA)
was used for these analyses.
3. Results
3.1. PSA metrics in PREVAIL
The median baseline PSA before treatment was 54 ng/ml
(range 0.1–3182 ng/ml) for men treated with enzalutamide
(n = 872) [1]. After 3 mo of enzalutamide treatment, a
Table 1 – Outcomes for the enzalutamide arm (N = 795)a stratified by PSA decline at month 3
Outcome Maximal confirmed PSA decline from baseline at month 3
No decline/decline
<30% (n = 94/795)
30% decline
(n = 701/795)
50% decline
(n = 639/795)
90% decline
(n = 307/795)
Best objective STR (CR + PR), % (95% CI)b 12.0 (4.5–24.3) 70.6 (65.1–75.6)c 74.8 (69.2–79.9)c 89.7 (82.8–94.6)c
Median time to PSA progression, mo (95% CI) 3.7 (3.7–4.6) 13.8 (11.3–14.0) 13.9 (13.8–16.6) 22.5 (16.8–NR)
HR for time to PSA progression (95% CI) 1.0 (reference) 0.17 (0.13–0.22) 0.16 (0.12–0.20) 0.10 (0.08–0.14)
Median rPFS, mo (95% CI) 7.9 (3.7–NR) NR (13.8–NR) NR (13.8–NR) NR (13.8–NR)
HR for rPFS (95% CI) 1.0 (reference) 0.20 (0.13–0.31) 0.17 (0.11–0.27) 0.10 (0.05–0.19)
Median OS, mo (95% CI) 23.1 (17.8–28.0) 32.4 (31.5–NR) NR (31.5–NR) NR (NR–NR)
HR for OS (95% CI) 1.0 (reference) 0.31 (0.22–0.42) 0.28 (0.20–0.39) 0.19 (0.12–0.28)
CI = confidence interval; CR = complete response; HR = hazard ratio; NR = not reached; OS = overall survival; PR = partial response; PSA = prostate-specific
antigen; RECIST = Response Evaluation Criteria In Solid Tumors; rPFS = radiographic progression-free survival; STR = soft-tissue response.
a Number of patients at risk at week 13.
b Patients with at least one target lesion identified per RECIST version 1.1 at screening are included in this analysis.
c p < 0.001 versus no PSA decline/PSA decline <30% based on Fisher’s exact test.
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had no PSA decline or a decline <30%, and 88% (701/795), 80%
(639/795), and 39% (307/795) of men had a confirmed
maximal PSA decline of 30%, 50%, and 90%, respectively
(Fig. 1). PSA flares (rise followed by a fall) after 3 mo of
enzalutamide treatment were rare (n = 4; <1%). The median
time to best overall PSA decline with enzalutamide was
4.6 mo (range 0.8–30.5 mo) for 854 patients who had at least
one postbaseline PSA measurement. However, 420 patients
of 854 patients (49%) had further PSA declines at month
6 compared with month 3, and 278 patients of 854 patients
(33%) had further PSA declines beyond month 6.
3.2. Prognostic association of PSA decline with clinical
outcomes
Key primary and secondary outcomes with enzalutamide
therapy are provided by PSA decline category in Table 1.
Compared with the no-decline or decline <30% group,
the groups with PSA declines of 30%, 50%, and 90%
within the first 3 mo of enzalutamide treatment had longer
times to PSA progression, rPFS, and OS (Fig. 2A–C) and
higher objective soft-tissue responses (all p < 0.001; Fig. 3).
The median time to PSA progression in the no-decline or
decline <30% group and the groups with confirmed PSA
declines of 30%, 50%, and 90% was 3.7 mo (95% CI 3.7–
4.6), 13.8 mo (95% CI 11.3–14.0), 13.9 mo (95% CI 13.8–16.6),
and 22.5 mo (95% CI 16.8–not reached [NR]), respectively
(Table 1). The median rPFS duration for the no-decline or
decline <30% group was 7.9 mo (95% CI 3.7–NR) and had not
been reached in the groups with confirmed PSA declines of
30%, 50%, and 90% (Table 1).
The median OS was 23.1 mo (range 17.8–28.0) for the no-
decline or decline <30% group and 32.4 mo (range 31.5–NR)
for the group with a PSA decline of 30%. Median OS was not
reached for the groups with confirmed PSA declines of 50%
and 90% (Table 1). The HR for OS was 0.31 (95% CI 0.22–0.42),
0.28 (95% CI 0.20–0.39), and 0.19 (95% CI 0.12–0.28) for the
groups with PSA declines of 30%, 50%, and 90%,
respectively (Table 1) versus the no-decline or decline
<30% group; OS was prolonged in the PSA decline groups
compared with the no-decline or decline <30% group.Compared with the no-decline or decline <30% group, groups
with a confirmed PSA decline of 30%, 50%, and 90% had a
greater probability of objective soft-tissue response, increas-
ing from 12% to 71%, 75%, and 90% (Table 1; Fig. 3). A complete
response in soft-tissue metastases was observed in 4%, 24%,
26%, and 45%, respectively, of these patients.
The results for best overall confirmed PSA decline at any
time during enzalutamide therapy were similar to those
seen after 3 mo of treatment. More specifically, the Kaplan-
Meier curves of rPFS and OS show great separations
between the PSA decline groups and the no-decline or
decline <30% group. The HR for rPFS was 0.18 (95% CI 0.12–
0.27), 0.15 (95% CI 0.1–0.23), and 0.07 (95% CI 0.04–0.13) for
the groups with declines of 30%, 50%, and 90%,
respectively, compared with the no-decline or decline
<30% group (Supplementary Fig. 1). The HR (95% CI) for OS
was 0.30 (0.22–0.40), 0.27 (0.20–0.37), and 0.18 (0.12–0.26)
for the groups with declines of 30%, 50%, and 90%,
compared with the no-decline or decline <30% group
(Supplementary Fig. 2). Both rPFS and OS were prolonged in
the PSA decline groups compared with the no-decline or
decline <30% group.
3.3. Association of PSA decline with QoL
Declines in PSA were strongly associated with delays in QoL
deterioration. Individual Kaplan-Meier curves for time to
degradation in FACT-P global QoL domain score are
provided in Fig. 4 and corresponding values in Supplemen-
tary Table 1. The median time to degradation in FACT-P
global QoL domain score was longer in the groups with
confirmed PSA declines of 30% (13.8 mo, 95% CI 11.2–16.6),
50% (14.0 mo, 95% CI 13.6–16.6), and 90% (16.5 mo, 95%
CI 11.2–24.9) than in the no-decline or decline <30% group
(5.6 mo, 95% CI 3.1–8.3). The corresponding HRs for FACT-P
global for the PSA decline groups were 0.58 (95% CI 0.43–
0.78), 0.56 (95% CI 0.41–0.75), and 0.51 (95% CI 0.37–0.71)
when compared with the no-decline or decline <30% group;
time to FACT-P degradation was prolonged in the PSA
decline groups compared with the no-decline or decline
<30% group. The median time to score degradation was also
longer for the physical, social/family, emotional, and
Fig. 2 – Kaplan-Meier plot of (A) time to PSA progression, (B) rPFS, and (C) OS by level of greatest confirmed PSA decline from baseline within the first
3 mo of treatment with enzalutamide. CI = confidence interval; dec. = decline; ENZA = enzalutamide; evt/cum. = events/cumulative events; HR = hazard
ratio; OS = overall survival; PSA = prostate-specific antigen; REF = reference; rPFS = radiographic progression-free survival.
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with PSA declines of 30%, 50%, and 90% than in the no-
decline or decline <30% group (Supplementary Table 1).
4. Discussion
In this post hoc analysis of PREVAIL, we found that the
magnitude of post-treatment confirmed maximal PSA
declines after 3 mo of therapy was strongly associated withbetter OS. In addition, PSA declines were strongly associated
with radiographic responses, including complete remission
of soft-tissue metastases, and delays in PSA and radio-
graphic progression and QoL deterioration. These data
provide important prognostic information to health care
providers who commonly use AR inhibitors such as
enzalutamide to treat patients with mCRPC before chemo-
therapy. Equally important, a PSA decline of <30% at 3 mo
was associated with poor prognosis, a low radiographic
Fig. 3 – Best objective soft-tissue response by level of greatest confirmed PSA decline from baseline within first 3 mo of treatment in enzalutamide
arm of PREVAIL (intention to treat patients with measurable disease). ORR = objective response rate; PSA = prostate-specific antigen. *p < 0.001 versus
no PSA decline/PSA decline <30% according to Fisher’s exact test.
Fig. 4 – Kaplan-Meier curve for exploratory analysis of time to degradation of the FACT-P global quality of life score among patients treated with
enzalutamide by PSA group confirmed at week 13 (intention-to-treat population). CI = confidence interval; dec. = decline; ENZA = enzalutamide; evt/
cum. = events/cumulative events; FACT-P = Functional Assessment of Cancer Therapy-Prostate; HR = hazard ratio; NR = not reached; PSA = prostate-
specific antigen; REF = reference.
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tion, and OS.
The strengths of this analysis are the large sample size
and the prospective and global multicenter nature of the
study cohort, permitting extrapolation of these results to
patients in many areas of the world. Second, given the lack
of PSA flares after 3 mo of enzalutamide therapy, a rise in
PSA after 3 mo of therapy is a likely indicator of worse
outcomes with enzalutamide, whereas a decline in PSAfollowing enzalutamide treatment can be reassuring to
patients and health care providers that therapy is associated
with clinical benefits. Ongoing PSA declines beyond 3 mo
were also common, illustrating that further reductions in
PSA continue long term in many patients and have
prognostic importance regarding clinical outcomes. A lack
of a PSA decline of 30% within 3 mo was found to be
associated with worse outcomes and was identified in 12%
(94/795) of patients treated with enzalutamide; thus, close
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are needed to ensure clinical benefits of continued therapy
in these patients. Such patients might benefit from
additional or alternative investigational approaches. How-
ever, we did observe that 12% of patients in the no-decline
or decline <30% group remarkably had a soft-tissue partial
or complete response, and 68% of such patients had
stabilization of their disease on imaging, illustrating that
PSA changes alone should not be used to decide whether to
discontinue AR inhibitors such as enzalutamide. Our results
extend and confirm similar findings observed in patients
with mCRPC receiving enzalutamide after docetaxel in the
AFFIRM trial [12], and reflect similar associations of post-
treatment PSA declines with better outcomes in men with
mCRPC and metastatic hormone-sensitive prostate cancer
treated with docetaxel [3,6,13,14]. The PCWG3 guidelines
support the continuation of systemic therapy until the
patient is no longer clinically benefiting, which may extend
beyond isolated PSA or imaging progression criteria
[15]. The limitations of this analysis include our focus on
enzalutamide. However, prior analyses have also documen-
ted clear associations between PSA declines and outcomes
in patients treated with docetaxel and abiraterone acetate,
but without demonstrating surrogacy for PSA declines for
OS [16,17]. In addition, we did not account for confounding
of prognostic factors that may be associated with a greater
probability of a PSA decline. A separate multivariable
analysis [18] demonstrated that baseline prognostic factors
and risk groups are highly associated with OS and PFS, as
well as confirmed PSA declines. Although PSA declines were
confirmed, approximately 10–30% of responding patients
still develop radiographic progression within 6–12 mo of
therapy despite having had a PSA decline. These findings
suggest that PSA declines may be transient in some men,
and that disease heterogeneity and resistance mechanisms
within the tumor require frequent assessments, including
imaging. For example, it was recently reported that nearly
25% of men with mCRPC treated with enzalutamide develop
radiographic progression without defined PSA progression
[19]. These data, and the observation noted above that some
patients experience radiographic responses without sub-
stantial PSA declines, illustrate the need for comprehensive
radiologic and clinical assessment of patients and their
disease status rather than reliance on PSA measurement
alone.
5. Conclusions
In conclusion, declines in PSA after 3 mo of enzalutamide
therapy are strongly associated with improvements in OS,
rPFS, and health-related QoL. The absence of a PSA decline of
30% after 3 mo of therapy identifies an important subset of
men with particularly poor prognosis, and few of these
patients will benefit in the long term despite a short-term
period of disease stability, whereas men with more
substantial PSA declines experienced longer-term delays
in progression and QoL deterioration. These PSA response
patterns thus identify men who might benefit from
alternative or additional therapies for better outcomes.Preliminary findings from this study were presented as a
poster discussion (Poster 787PD) at the Annual Congress of
the European Society for Medical Oncology, September 8–
12, 2017, in Madrid, Spain.
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